Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Lei Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6247-2420; OpenAlex author ID A5100333487. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  2. Long noncoding RNA SOX2OT promotes pancreatic cancer cell migration and invasion through destabilizing FUS protein via ubiquitination. Co-author DOI 10.1038/s41420-021-00640-8↗
  3. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  4. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  5. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  6. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗
  7. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  8. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Co-author DOI 10.2147/ott.s157759↗
  9. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 7 shared papers, 2017–2025 · strength 0.73
  2. Hao Yuan · 6 shared papers, 2017–2025 · strength 0.66
  3. Qun Chen · 5 shared papers, 2019–2025 · strength 0.61
  4. Wanli Ge · 5 shared papers, 2018–2025 · strength 0.60
  5. Lingdong Meng · 4 shared papers, 2019–2025 · strength 0.52
  6. Xumin Huang · 4 shared papers, 2019–2025 · strength 0.52
  7. Peng Shen · 4 shared papers, 2019–2025 · strength 0.52
  8. Jingjing Zhang · 5 shared papers, 2017–2021 · strength 0.49
  9. Yi Miao · 5 shared papers, 2017–2020 · strength 0.42
  10. Guodong Shi · 5 shared papers, 2017–2020 · strength 0.42
  11. Yi Miao · 3 shared papers, 2019–2025 · strength 0.41
  12. Zipeng Lu · 3 shared papers, 2017–2020 · strength 0.23
  13. Meng Cao · 2 shared papers, 2019–2020 · strength 0.17
  14. Tianfang Xia · 2 shared papers, 2019–2020 · strength 0.17
  15. Pengbo Zhang · 2 shared papers, 2019–2020 · strength 0.17
  16. Pengfei Wu · 2 shared papers, 2019–2020 · strength 0.17
  17. Xinquan Wu · 2 shared papers, 2019–2020 · strength 0.17
  18. Baobao Cai · 2 shared papers, 2019–2020 · strength 0.17
  19. Xiong-Fei Zhang · 1 shared paper, 2021 · strength 0.16
  20. Yan Wang · 1 shared paper, 2021 · strength 0.16
  21. Yang Feng Wu · 2 shared papers, 2017–2018 · strength 0.14
  22. Kuirong Jiang · 1 shared paper, 2020 · strength 0.11
  23. Shouji Cao · 1 shared paper, 2020 · strength 0.09
  24. Lei Xu · 1 shared paper, 2020 · strength 0.09
  25. Chuang Yang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.